600276 恒瑞医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)10.96810.99110.72813.83122.896
总资产报酬率 ROA (%)10.0299.9889.57012.24520.320
投入资产回报率 ROIC (%)10.70910.64810.33213.55122.683

边际利润分析
销售毛利率 (%)85.96784.55283.61285.55687.926
营业利润率 (%)26.47621.51619.32718.00725.265
息税前利润/营业总收入 (%)22.97718.35616.44015.93624.207
净利润/营业总收入 (%)22.86518.74617.93217.30922.747

收益指标分析
经营活动净收益/利润总额(%)100.24798.68388.90592.08093.577
价值变动净收益/利润总额(%)-0.430-2.30211.6895.5905.191
营业外收支净额/利润总额(%)-5.083-5.202-3.615-4.445-1.618

偿债能力分析
流动比率 (X)8.99812.2528.5008.8757.437
速动比率 (X)8.33711.3467.8278.1686.966
资产负债率 (%)8.2896.2849.3419.40911.352
带息债务/全部投入资本 (%)2.8110.9724.0481.5861.043
股东权益/带息债务 (%)3,443.31110,140.5082,350.5206,155.2159,435.026
股东权益/负债合计 (%)1,092.4011,470.724955.631947.456773.713
利息保障倍数 (X)-10.357-8.756-7.428-12.216-36.941

营运能力分析
应收账款周转天数 (天)72.67387.44489.03867.44264.771
存货周转天数 (天)230.862243.282250.552201.115181.944